PatientBase ™… .. (Decision Resources ’ Customizable Epidemiology Database)

1. PatientBase™…..(Decision Resources’ Customizable Epidemiology Database) © Decision Resources, Inc., 2005

2. PatientBase™ • Features • Methodology • Demonstration • Applications / Uses • Appendix

3. PatientBase™

4. What is PatientBase™ • Online database of 103 diseases and 153 indications • Therapeutic Coverage • Geographic Focus • United States • Japan • France, Germany, Italy, Spain and United Kingdom • Frequency of Outputs • Released quarterly with most indications updated annually • Created, analyzed and validated by DR’s well-credentialed Epidemiology staff 1. Cancer 4. Immune & Inflammatory 2. Cardiovascular 5. Infectious 3. CNS 6. High Interest Diseases like Obesity, Osteoporosis, Erectile Dysfunction etc.

5. PatientBase™ Features • 10 year forecast – 2004 to 2014 • Prevalent cases / Incident cases • Diagnosed • Drug treated • Five-year age cohorts • By gender • Types of sub-population (Co-morbidity, Severity, Seasonality etc.) • Corresponding UN population • Data portability into Excel • Complete access to Sources & Methodology behind the data

6. PatientBase™ Development Methodology • Epidemiologists conduct exhaustive secondary literature searches • Several hundred studies are reviewed for each indication • If appropriate, analyses of primary data sources are conducted • Epidemiologists choose the best country-specific population-based studies • Size and representativeness of subject population and rigor of case ascertainment methods • Academic epidemiological methods are applied in conducting analyses to determine methodology • Age- and gender-specific incidence or prevalence is applied to age- and gender-specific United Nations population estimates • For each country to reflect influence of demographic changes over time on patient populations

7. Epidemiology Data Sources DR’s expert epidemiologists consult primary data sources, team with expert reviewers, and review hundreds of secondary data sources for estimating incidence/prevalence trends Bundes-Gesundheitssurvey 98 ECA

8. PatientBase™ - Demonstration

9. PatientBase™ – Demonstration (First Page) Begin by selecting an indication (Up to 16 indications at one time) Click to go to the Epi Query page

10. PatientBase™ – Demonstration (Epi Query)

11. PatientBase™ – Demonstration (Epi Query)Step 1

12. PatientBase™ – Demonstration (Epi Query)Step 2 • Subpopulation is the distribution of Prevalent/Incident cases specific to an Indication • provided for more than half of all diseases and conditions • Co-morbidity • Severity • Laboratory measure • Seasonality • Etiology • Pathogen type • Infection site • Treatment type

13. PatientBase™ – Demonstration (Epi Query)Step 3 • Prevalent cases: all patients with the disease/condition at a point in time • Incident cases: all patients newly diagnosed with the disease/condition • Drug-treated cases: all diagnosed patients who are receiving pharmacotherapy • Corresponding U.N. population data: the total number of United Nations-estimated people in the population that corresponds to the cases of people with the disease or condition

14. PatientBase™ – Demonstration (Epi Query)Step 4 • Regional total: total regional patient populations (United States, Europe, Japan) • Country total: total country patient populations (United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) • Country and gender detail: breakout of country-specific patient populations by male and female • Country, gender, and age detail: breakout of country-specific patient populations by male and female and by 5-year age breakouts

15. PatientBase™ – Demonstration (Epi Query)Step 5 • Formatted table: data are presented in attractive table for ease of use and presentation • Raw data spreadsheet: data are presented in raw table which is easiest to manipulate when exported to Excel • Both formats can be exported to Excel for further manipulation • Forecast period: forecast is presented in 5 year increments • 2004 2009 2014 • Client can choose to view annualized forecasts through 2014 or forecasts of individual years

16. PatientBase™ – Demonstration (Epi Results)

17. PatientBase™ – Demonstration (Epi Results)Tool Bar • Methodology: thorough and transparent discussions of overall and country-specific methodologies used to obtain patient population estimates and subpopulations • Bibliography: complete bibliography of all sources analyzed for the methodology • Key Sources: country-specific list of primary sources used to estimate key patient populations and subpopulations

18. PatientBase™ – Application / Uses • Estimate the number of people with drug-treatable disease or condition over time • Percent diagnosed • Percent treated • Segment cases by age, gender, stage, severity, genetic factor, disease attribute, co-morbidity or country • Annualized population forecasts • Compare populations across Indications

19. Support & Services • DR’s highly skilled Epidemiology staff will answer any questions regarding PatientBase™ • Staff members with over 50 years combined work experience • DR’s Consulting Group along with Epidemiology staff can assist in any customized Epidemiology work • Additional Indications • Geography not covered in PatientBase™

20. Acute Myeloid Leukemia Bladder Cancer-Superficial Bladder Cancer-Metastatic Bladder Cancer-Muscle-Invasive Breast Cancer-Stage I Breast Cancer-Stage II Breast Cancer-Stage III Breast Cancer-Stage IV Cervical Cancer-Stage I Cervical Cancer-Stage III Cervical Cancer-Stage III Cervical Cancer-Stage IV Chronic Lymphocytic Leukemia-High Risk Chronic Lymphocytic Leukemia-Intermed. Risk Chronic Lymphocytic Leukemia-Low Risk Chronic Myelogenous Leukemia Colon Cancer-Stage I Colon Cancer-Stage II Colon Cancer-Stage III Colon Cancer-Stage IV Colorectal Cancer-Stage I Colorectal Cancer-Stage II Colorectal Cancer-Stage Colorectal Cancer-Stage IV Oncology Indications in PatientBase™- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.) Appendix

21. Esophageal Cancer - Distant Esophageal Cancer - Limited Esophageal Cancer - Regional Esophageal Cancer - Unknown Glioma Liver Cancer - Distant Liver Cancer - Limited Liver Cancer - Regional Liver Cancer - Unknown Malignant Melanoma-Stage I Malignant Melanoma-Stage II Malignant Melanoma-Stage III Malignant Melanoma-Stage IV Multiple Myeloma-Stage I Multiple Myeloma-Stage II Multiple Myeloma-Stage III Non-Hodgkin's Lymphoma-Aggressive Non-Hodgkin's Lymphoma-Indolent Non-Small-Cell Lung Cancer-Stage I Non-Small-Cell Lung Cancer-Stage II Non-Small-Cell Lung Cancer-Stage III Non-Small-Cell Lung Cancer-Stage IV Ovarian Cancer-Stage I Ovarian Cancer-Stage II Ovarian Cancer-Stage III Ovarian Cancer-Stage IV Oncology Indications in PatientBase™ Cont.- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.) Appendix

22. Pancreatic Cancer-Distant Pancreatic Cancer-Localized Pancreatic Cancer-Regional Prostate Cancer-Stage I Prostate Cancer-Stage II Prostate Cancer-Stage III Prostate Cancer-Stage IV Rectal Cancer-Stage I Rectal Cancer-Stage II Rectal Cancer-Stage III Rectal Cancer-Stage IV Renal Cell Carcinoma-Stage I/II Renal Cell Carcinoma-Stage III Renal Cell Carcinoma-Stage IV Small-Cell Lung Cancer-Extensive Small-Cell Lung Cancer-Limited Stomach Cancer - Distant Stomach Cancer - Limited Stomach Cancer - Regional Stomach Cancer - Unknown Oncology Indications in PatientBase™ Cont.- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.) Appendix

23. Central Nervous System Indications in PatientBase™- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.) Appendix • Acute Ischemic Stroke • Alzheimer’s Disease • Attention-Deficit/Hyperactivity Disorder-Adult • Attention-Deficit/Hyperactivity Disorder-Pediatric • Bipolar Disorder • Chronic Low Back Pain • Dementia • Epilepsy • Generalized Anxiety Disorder • Insomnia • Major Depression • Migraine (Prophylaxis) • Mild Cognitive Impairment • Minor Depression • Multiple Sclerosis (Chronic-Progressive) • Multiple Sclerosis (Relapsing-Remitting) • Narcolepsy • Obsessive-Compulsive Disorder • Obstructive Sleep Apnea • Osteoarthritic Pain • Panic Disorder • Parkinson’s Disease • Post-operative Pain • Restless Legs Syndrome • Rheumatoid Arthritic Pain • Schizophrenia • Social Anxiety Disorder • Postherpetic Neuralgia • Painful Diabetic Neuropathy • HIV-Related Neuropathic Pain

24. Infectious Diseases Indications in PatientBase™- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.) Appendix • Acute Exacerbations of Chronic Bronchitis • Community-Acquired Pneumonia • Hepatitis B • Hepatitis C • Herpes Zoster • HIV-Newly Diagnosed Population • Human Immunodeficiency Virus • Influenza A and B • Methicillin-Resistant Staph A • Sepsis • Complications of Soft Skin Tissue Infection

25. Cardiovascular Indications in PatientBase™- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.) Appendix • Acute Heart Failure • Acute Myocardial Infarction • Atrial Fibrillation • Chronic Heart Failure • Coronary Heart Disease • Dyslipidemia • Hypertension • Peripheral Arterial Disease • Post-Myocardial Infarction • Pulmonary Arterial Hypertension • Non-ST-Elevation Myocardial Infarction • Venous Thromboembolism

26. Immune and Inflammatory Disorders Indications in PatientBase™- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.) Appendix • Allergic Rhinitis • Asthma • Crohn’s Disease • Diabetic Nephropathy • Eczema/ Atopic Dermatitis • Metabolic Syndrome • Fibromyalgia • Osteoarthritis • Psoriasis • Rheumatoid Arthritis • Systemic Lupus Erythematosus • Type 1 Diabetes • Type 2 Diabetes • Ulcerative Colitis • Urticaria

27. High-Interest Disease in PatientBase™- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.) Appendix • Age-Related Macular Degeneration (Wet) • Benign Prostatic Hyperplasia • Chronic Obstructive Pulmonary Disease • Diabetic Neuropathy • Diabetic Retinopathy • Erectile Dysfunction • Female Sexual Dysfunction • Gastroesophageal Reflux Disease • Irritable Bowel Syndrome • Obesity • Osteoporosis • Urinary Incontinence (Urge) • Urinary Incontinence (Stress)

28. For Further Information North America Mr. Bob Fucile Tel. 781-296-2500 Fax 781-296-2550 rfucile@dresources.com Decision Resources, Inc. 260 Charles Street Waltham, MA 02453 Europe Ms. Vera Bisegna Tel. +32-2-351-10-79 Fax +32-2-351-23-47 vbisegna@decisionresources.be Decision Resources International, Inc. Avenue des Chasseurs, 1 1410 Waterloo, Belgium Japan Ms. Makiko Yoshimoto Tel. +81-3-5401-2615 Fax +81-3-5401-2617 makiko@dresources.jp Decision Resources International, Inc. Fukide Building F4 4-1-13 Toranomon Minato-ku, Tokyo 105-0001 Japan